Tofacitinib Response in Ulcerative Colitis - a Real World Prospective Multi-center Study (TOUR)
TOUR: Tofacitinib Response in Ulcerative Colitis - a Real World Prospective Multi-center Study
Sponsor: Pfizer
Terminated
Futility; recruitment to slow to justify longer study duration
Listed as NCT03772145, this observational or N/A phase trial focuses on Ulcerative Colitis and remains terminated or withdrawn. Sponsored by Pfizer, it has been updated 9 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Feb 2024 — Jul 2024 [monthly]
Terminated
Status: Enrolling By Invitation → Terminated
-
May 2023 — Feb 2024 [monthly]
Enrolling By Invitation
-
Apr 2022 — May 2023 [monthly]
Enrolling By Invitation
▶ Show 4 earlier versions
-
Feb 2021 — Apr 2022 [monthly]
Enrolling By Invitation
-
Jan 2021 — Feb 2021 [monthly]
Enrolling By Invitation
-
Feb 2020 — Jan 2021 [monthly]
Enrolling By Invitation
-
Jan 2019 — Feb 2020 [monthly]
Enrolling By Invitation
First recorded
Nov 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
- University of North Carolina, Chapel Hill
For direct contact, visit the study record on ClinicalTrials.gov .